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Background: RIPK4 and IRF6 are important for epidermal development. However, whether they function together to
regulate keratinocyte differentiation has not been addressed.
Results: RIPK4 directly activates IRF6, resulting in expression of the transcriptional regulators GRHL3 and OVOL1.
Conclusion: RIPK4 and IRF6 promote keratinocyte differentiation by functioning as a signaling axis.
Significance: This study reveals how mutations in RIPK4 may cause epidermal disorders.
Receptor-interacting protein kinase 4 (RIPK4) and interferon
regulatory factor 6 (IRF6) are critical regulators of keratinocyte
differentiation, and their mutation causes the related develop-
mental epidermal disorders Bartsocas-Papas syndrome and
popliteal pterygium syndrome, respectively. However, the sig-
naling pathways in which RIPK4 and IRF6 operate to regulate
keratinocyte differentiation are poorly defined.Herewe identify
and mechanistically define a direct functional relationship
between RIPK4 and IRF6. Gene promoter reporter and in vitro
kinase assays, coimmunoprecipitation experiments, and confo-
cal microscopy demonstrated that RIPK4 directly regulates
IRF6 trans-activator activity and nuclear translocation. Gene
knockdown and overexpression studies indicated that the
RIPK4-IRF6 signaling axis controls the expression of key tran-
scriptional regulators of keratinocyte differentiation, including
Grainyhead-like 3 and OVO-like 1. Additionally, we demon-
strate that the p.Ile121Asn missense mutation in RIPK4, which
has been identified recently in Bartsocas-Papas syndrome,
inhibits its kinase activity, thereby preventing RIPK4-mediated
IRF6 activation and nuclear translocation. We show, through
mutagenesis-based experiments, that Ser-413 and Ser-424 in
IRF6 are important for its activation by RIPK4. RIPK4 is also
important for the regulation of IRF6 expression by the protein
kinase C pathway. Therefore, our findings not only provide
important mechanistic insights into the regulation of keratino-
cyte differentiation by RIPK4 and IRF6, but they also suggest
onemechanismbywhichmutations inRIPK4may cause epider-
mal disorders (e.g. Bartsocas-Papas syndrome), namely by the
impaired activation of IRF6 by RIPK4.
The epithelial cells that cover the external surfaces of the
body (e.g. epidermal and oral keratinocytes) serve a number of
important functions. One such function is to provide a barrier
defense against mechanical trauma, chemicals, and infection
(1). The formation of this barrier during embryonic develop-
ment relies upon a tightly regulated balance between keratino-
cyte proliferation and differentiation. Proliferation is restricted
to the basal layer, where epidermal stem cells periodically lose
the capacity to proliferate and initiate a program of terminal
keratinocyte differentiation andmigrate toward the surface (2).
The development of various ectodermal structures (e.g. lips and
mouth, digits, and external genitalia) also relies upon these pro-
cesses being tightly regulated (2). Keratinocyte proliferation
and differentiationmust also be tightly regulated post-develop-
ment to maintain barrier integrity and to prevent pathological
conditions (e.g. squamous cell carcinoma) (3).
Interferon regulatory factor 6 (IRF6) is a critical transcrip-
tional regulator of keratinocyte differentiation (4–6). Irf6-
deficient mice exhibit a range of epidermal defects. For
instance, their epidermis is characterized by a greatly
expanded spinous layer and absence of the granular and cor-
nified layers, resulting in defective epidermal barrier func-
tion (4). Irf6-deficient mice also have epidermal adhesions at
several sites, including in the oral cavity. Although the sig-
naling pathways in which IRF6 operates are unclear, its tran-
scriptional activation of the transcription factors Grainy-
head-like 3 (GRHL3) and OVO-like 1 (OVOL1) is important
for keratinocyte differentiation (7, 8).
Receptor interacting protein kinase 4 (RIPK4) is also a critical
regulator of keratinocyte differentiation (9, 10). The external
orifices of Ripk4-deficientmice, including themouth, are fused.
The epidermis is greatly expanded and dysregulated, and the
mice die at birth, most likely from suffocation (9, 10). Prior
studies have indicated that RIPK4 functions in several signaling
pathways, including the PKC,NF-B, andWnt/-catenin path-
ways (10–16).
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Mutations in IRF6 cause popliteal pterygium syndrome (17),
a developmental epidermal disorder characterized by orofacial
clefting, skin webbing, syndactyly, and genital deformities (18).
Mutations in RIPK4 have been identified recently in Bartsocas-
Papas syndrome (BPS)3 (19, 20). BPS is a more severe form of
popliteal pterygium and causes death early in life (21, 22).
RIPK4 and IRF6 mutations have also been identified in squa-
mous cell carcinoma (23).
How RIPK4 and IRF6 regulate keratinocyte differentiation is
not well understood. However, given the phenotypic similari-
ties betweenRipk4- and Irf6-deficientmice, alongwith the sim-
ilarities in the developmental defects in individuals with muta-
tions inRIPK4 and IRF6,we sought to establishwhether a direct
functional relationship exists between these two proteins. We
demonstrate here that not only do RIPK4 and IRF6 function in
the same PKC-regulated signaling pathway to promote kerati-
nocyte differentiation, but RIPK4 also directly activates IRF6.
We also provide insights into how a specific missensemutation
in RIPK4 may cause BPS.
EXPERIMENTAL PROCEDURES
Reagents—Cell culture medium and supplements, FCS,
SuperScript III reverse transcriptase, random primers, dNTPs,
TaqMan Universal Master Mix II, Lipofectamine RNAiMAX,
Lipofectamine 2000, Silencer Select RIPK4 siRNA and control
non-targeting siRNA, precast 10% NuPAGE gels, mouse
anti-V5 antibodies, Alexa Fluor 488-conjugated goat anti-rab-
bit IgG and Alexa Fluor 594-conjugated goat anti-mouse IgG
antibodies, and ProLong Gold Antifade reagent (containing
DAPI) were from Invitrogen. [-32P]ATP (3000 Ci/mmol) was
from PerkinElmer Life Sciences. FuGENE6, Passive Lysis
Buffer, and theDual-Glo luciferase assay systemwere fromPro-
mega. The QuikChange II site-directed mutagenesis kit was
from Agilent Technologies, and the mutagenic primers were
synthesized byGeneWorks. cOmplete protease inhibitors were
from Roche. The ON-TARGETplus IRF6 siRNA and non-tar-
geting control siRNAwere fromMillennium Science. The anti-
IRF6 and anti-PCNAantibodieswere fromCell SignalingTech-
nology. Anti--tubulin and HRP-conjugated anti-FLAG (M2)
antibodies and anti-FLAG-agarose were from Sigma-Aldrich.
Anti-HSP90 antibodywas fromBDBiosciences, and anti-ERK2
antibody was from Santa Cruz Biotechnology.
Expression Vectors and Mutagenesis—The IRF6 expression
vectors pEF-HA-IRF6 (expresses an N-terminal HA-tagged
version of human IRF6), pEF-HA-IRF6 S413A (Ser-413
replaced by alanine), pEF-HA-IRF6 S424A (Ser-424 replaced by
alanine), pEF-HA-IRF6 S413A/S424A (Ser-413 and Ser-424
replaced by alanine), pEF-HA-IRF6 S413E (Ser-413 replaced by
glutamic acid), pEF-HA-IRF6 S424E (Ser-424 replaced by glu-
tamic acid), pEF-HA-IRF6 S413E/S424E (Ser-413 and Ser-424
replaced by glutamic acid), and pEF-V5-IRF6 (expresses an
N-terminal V5-tagged version of IRF6) have been described
previously (24). Expression vectors encoding FLAG-tagged ver-
sions of wild-type and kinase-dead (K51R) mouse Ripk4 were
provided by Dr. Shiv Pillai (Harvard Medical School) (12). The
Ripk4 expression vector pFLAG-Ripk4 I121N (Ile-121 replaced
by asparagine) was created using the primer pair 5-GGGACC
TGC GCT TTC GCA ACG TGC ACG AG-3 and 5-CTC
GTG CAC GTT GCG AAA GCG CAG GTC CC-3 and a
QuikChange II site-directed mutagenesis kit. The GST expres-
sion vector pGEX-IRF6CTD (expresses theC-terminal domain
of IRF6 fused toGST) was created by PCR using the primer pair
5-ACG GAA TTC GCT CGG ATG ATC TAC GAG ATG-3
and 5-CAG AAG CTT TTA CTG GGG AGG CAG GGC
AG-3. The PCR product was digested with EcoRI and HindIII
and cloned into pGEX2TH, and then the sequencewas verified.
Bacterial Expression and Purification of GST Proteins—
Transformed BL21(DE3) Escherichia coli were grown at 37 °C
in 2YT broth (1.6% tryptone, 1% yeast extract, 0.5% NaCl, pH
7.0) with constant shaking. When the culture A600 reached
0.6, protein expression was induced with isopropyl 1-thio--
D-galactopyranoside (0.4mM), and the culture was incubated at
25 °C for 2–3 h with constant shaking. The bacteria were lysed
by sonication in ice-cold PBS containing 1% Triton X-100,
DNase I (30 g/ml) and protease inhibitors. The lysates were
clarified by centrifugation (27,000  g for 40 min at 4 °C), and
the GST proteins (GST-IRF6 CTD and GST) were purified on
an FPLC system using GSTrap FF columns (GE Healthcare)
and concentrated using Amicon Ultra-4 centrifugal filters
(Millipore).
Cell Culture—The human oral keratinocyte cell line OKF6/
TERT-2 (25) was cultured in keratinocyte serum-free medium
supplemented with 25 g/ml bovine pituitary extract, 2 ng/ml
EGF, 0.4 mMCaCl2, 100 units/ml penicillin, 100g/ml strepto-
mycin, and 2mMGlutaMax-1. Primary human epidermal kera-
tinocytes (Lonza) were cultured in KGM-GoldTM medium
according to the protocol of the supplier. HEK293T cells were
cultured in DMEM supplemented with 10% FCS, 100 units/ml
penicillin, 100 g/ml streptomycin, and 2 mM GlutaMax-1.
Cells were cultured at 37 °C in a humidified atmosphere of 5%
CO2.
Cell Lysis and Western Blotting—Cells were washed twice
with ice-cold PBS and then lysed (20mMTris-HCl (pH 7.4), 150
mM NaCl, 1 mM EDTA, 1% Nonidet P-40, 10% glycerol, 10 mM
NaF, 10 mM -glycerol phosphate, and cOmplete protease
inhibitors) on ice for 60 min. The lysates were clarified by cen-
trifugation (13,000 g for 10 min at 4 °C), and protein concen-
trations were measured using a protein assay kit (Bio-Rad).
Lysates were subjected to electrophoresis on 10% NuPAGE
gels, followed by Western blotting according to standard pro-
tocols. Immunoreactive bands were visualized using ECL
reagents (Millipore) and a LAS-3000 Imager (Fujifilm) or by
exposure to x-ray film (Fujifilm). Films were scanned using a
GS-800 calibrated imaging densitometer (Bio-Rad).
ImmunoprecipitationAssays—V5-IRF6was immunoprecipi-
tated by incubating 1 mg of cell lysate with 1 g of anti-V5
antibody and 20 l of protein G-Sepharose for 4 h at 4 °C with
constant mixing. FLAG-Ripk4 was immunoprecipitated by
incubating 1 mg of cell lysate with 10 l of anti-FLAG-agarose
for 4 h at 4 °C with constant mixing. In both cases, the beads
were then washed four times with lysis buffer.
3 The abbreviations used are: BPS, Bartsocas-Papas syndrome; PMA, phorbol
12-myristate 13-acetate; CTD, C-terminal domain; PCNA, proliferating cell
nuclear antigen; IVL, involucrin; DMSO, dimethyl sulfoxide.
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tates were incubated for 30 min at 30 °C in kinase assay buffer
(20 mM Hepes (pH 7.4), 25 mM MgCl2, 3 mM MnCl2, 10 mM
-glycerol phosphate, 10 M ATP, and 10 Ci of [-32P]ATP)
containing 2 g of GST-IRF6 CTD or GST. Reactions were
terminated by the addition of SDS-PAGE sample buffer and
heating at 95 °C for 5 min. Aliquots of the reactions were then
subjected to SDS-PAGE. The gels were stained with colloidal
Coomassie G-250 and dried, and 32P incorporation was detected
using a Typhoon Trio PhosphorImager (GEHealthcare).
Gene Promoter Reporter Assays—HEK293T cells were seeded
in 12-well tissue culture plates at a density of 3 105 cells/well
and transfected (in duplicate) the next day using FuGENE6
transfection reagent. The total amount of plasmid in each
transfection was kept constant using empty vector. The cells
were lysed 24 h post-transfection with passive lysis buffer and
assayed for firefly and Renilla luciferase activity using the Dual-
Glo luciferase assay system. Renilla luciferase activity was used
to normalize transfection efficiencies. The IFN gene promoter
reporter plasmid was provided by Dr. Ashley Mansell (Monash
Institute of Medical Research). The NF-B-dependent E-selec-
tin (ELAM-1) gene promoter reporter plasmidwas as described
previously (26). The control Renilla reporter plasmid, pRL-TK,
was from Promega.
Immunofluorescent Staining and Confocal Microscopy—
OKF6/TERT-2 cells and HEK293T cells (seeded on glass cov-
erslips) were fixed with 4% paraformaldehyde, solubilized with
0.1% Triton X-100, and blocked in 5% goat serum. The cells
were then incubated overnight (at 4 °C) with a rabbit anti-IRF6
antibody, a mouse anti-FLAG antibody, or a mouse anti--tu-
bulin antibody for 16 h at 4 °C. Following three washes with
PBS, the cells were incubated with an Alexa Fluor 488-conju-
gated goat anti-rabbit IgG antibody or an Alexa Fluor 594-con-
jugated goat anti-mouse IgG antibody for 60 min at room tem-
perature. The cells were washed three times with PBS and
finallymounted on glassmicroscope slides using ProLongGold
Antifade reagent containing DAPI. Mounted coverslips were
allowed to cure in the dark for 24 h. Images were acquired on an
Olympus FV1000 scanning confocal microscope. No anti-IRF6
or anti-FLAG staining was apparent in HEK293T cells trans-
fected with empty vector only. The effects of phorbol 12-myris-
tate 13-acetate (PMA) on IRF6 subcellular localization were
analyzed using ImageJ software. Three random fields of cells
were analyzed for each treatment condition. Binary images
were obtained by thresholding to define the nuclear region of
interest, which was subsequently used for measuring IRF6
nuclear fluorescence. Thereafter, IRF6 cytoplasmic fluores-
cence was determined by subtracting the nuclear fluorescence
from the total cell fluorescence. IRF6 nuclear localization was
calculated by dividing the nuclear fluorescence by the cytoplas-
mic fluorescence and is presented as a ratio of nuclear to cyto-
plasmic IRF6.
Real-time PCR—Total RNA was purified using an RNAeasy
mini kit (Qiagen). RNA (1 g) was reverse-transcribed into
cDNA using random primers and SuperScript III reverse tran-
scriptase. Real-time PCR was performed (in triplicate) with an
Applied Biosystems Prism 7900HT sequence detection system
and TaqMan assays (Invitrogen) for the following genes:
GRHL3 (Hs00297962_m1), IRF6 (Hs00196213_m1), IVL
(Hs00902520_m1),KRT13(Hs00999762_m1),MAD1(Hs00965581_
m1), OVOL1 (Hs00190060_m1), RIPK4 (Hs01062501_m1),
and Ripk4 (Mm00458366_m1). Messenger RNA levels relative
to those of the endogenous control gene, HPRT, were calcu-
lated using the Ct method (27).
Gene Silencing and Overexpression—A reverse transfection
protocol was used for the transfection of OKF6/TERT-2 cells
and primary human epidermal keratinocytes. For gene silenc-
ing, siRNAs were diluted to 120 nM with 100 l of Opti-MEM I
reduced serum medium (Invitrogen) and then mixed with 100
l of Opti-MEM medium containing 1 l of Lipofectamine
RNAiMAX transfection reagent, followed by incubation at
room temperature for 20 min. For gene overexpression, the
expression plasmid (1g of total plasmid) was diluted in 100l
of Opti-MEM medium and then mixed with 100 l of Opti-
MEMmedium containing 1l of Lipofectamine 2000 transfec-
tion reagent, followed by incubation at room temperature for
20 min. For both gene silencing and overexpression, keratino-
cytes (2–5 105 cells in 1ml of antibiotic-free growthmedium)
were seeded into 12-well plates, and the transfection mixture
was added. For gene knockdown experiments, themediumwas
replaced after 16 h, and the cells were treated with PMA 48 or
72 h post-transfection. For gene overexpression experiments,
the cells were treated with PMA 24 h post-transfection without
medium change.
Statistical Analysis—Data combined from three or more
independent experiments are given as mean  S.E. Statistical
analyses were performed using GraphPad Prism software ver-
sion 6.01 (GraphPad Software, La Jolla, CA). Differences
between two groups were evaluated using Student’s t test. For
multiple comparisons, statistical analysis was performed using
a one-way analysis of variance and Sidak’s or Dunnett’s test as a
post hoc test. p 0.05 was considered to be statistically
significant.
RESULTS
Regulation of IRF6 by RIPK4—To establish whether a func-
tional relationship exists between RIPK4 and IRF6, we first
investigated whether the trans-activator activity of IRF6 is reg-
ulated by RIPK4. IRF6 trans-activator activity, which was mea-
sured using an IFN gene promoter reporter plasmid (24), was
strongly induced, in a concentration-dependent manner, by
wild-type RIPK4 (Fig. 1A) but not by the kinase-dead RIPK4
mutant RIPK4 K51R (Fig. 1B). Consistent with earlier findings
(13, 15), RIPK4 also activated NF-B in a concentration- (Fig.
1C) and kinase-dependent (Fig. 1D) manner.
The phosphorylation of regulatory serine residues in the
C-terminal domain (CTD) of IRFs represents a critical step in
their inducible activation (28). To determine whether RIPK4
can directly phosphorylate the IRF6 CTD, in vitro kinase assays
were performed using a GST-IRF6 CTD fusion protein as sub-
strate. RIPK4 phosphorylated the GST-IRF6 CTD protein but
not the GST control (Fig. 1E). Because of the instability of the
GST-IRF6 CTD fusion protein, a degradation product was also
evident in the Coomassie-stained gel (Fig. 1E). The ability of
RIPK4 to interact with IRF6 was also investigated by perform-
ing coimmunoprecipitation experiments. IRF6 interacted,
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either directly or as part of a complex, with wild-type RIPK4.
However, no interaction with the RIPK4 K51R mutant was
detected (Fig. 1F, top panel). Because of autophosphorylation
(12), a doublet was detected when wild-type, but not kinase-
dead, RIPK4 was expressed in HEK293T cells (Fig. 1F, bottom
panel).
The ability of RIPK4 to regulate IRF6 nuclear translocation
was also tested. IRF6 was detected in the cytoplasm of trans-
fected cells. However coexpression of wild-type RIPK4, but not
RIPK4 K51R, resulted in the partial nuclear translocation of
IRF6 (Fig. 1G). RIPK4 localized exclusively to the cytoplasm,
where it exhibited a degree of colocalization with the cytoplas-
mic pool of IRF6 (Fig. 1G). Collectively, the results in Fig. 1
indicate that RIPK4 can directly activate IRF6 and induce its
nuclear translocation.
Characterization of PKC-regulated Oral Keratinocyte Differentia-
tion—PKC is an important regulator of keratinocyte differenti-
ation (29–33), and previous studies have indicated that RIPK4
functions in the PKC pathway (10–14). PMA is a potent PKC
activator and a strong inducer of keratinocyte terminal differ-
entiation (34). Therefore, we assessed whether PMA treatment
of OKF6/TERT-2 cells (hereafter referred to as OKF6 cells),
which have the characteristics of primary human oral keratino-
cytes (25), would provide a suitable model for oral keratinocyte
differentiation. PMA treatment induced marked morphologi-
cal changes (Fig. 2A) and strongly suppressed cell proliferation
(Fig. 2B). This correlated with decreased levels of the prolifer-
ation marker proliferating cell nuclear antigen (PCNA) (Fig. 2,
C andD). Differentiationwas further assessed bymeasuring the
expression levels of the early and late terminal differentiation
markers involucrin (IVL) and keratin 13 (KRT13), respectively
(35, 36). Both genes were strongly up-regulated by PMA treat-
ment (Fig. 2, E and F). GRHL3, OVOL1, and mitotic arrest-
deficient 1 (MAD1), which themselves are important transcrip-
tional regulators of keratinocyte differentiation (37–42), were
also up-regulated in PMA-treated cells (Fig. 2, G–I). OVOL1
expression was most rapidly up-regulated (Fig. 2H), whereas
the induction of MAD1 gene expression was slowest (Fig. 2I).
Collectively, these data demonstrate that PMA treatment of
OKF6 cells provides a good model for investigating the regula-
tion of keratinocyte differentiation by RIPK4 and IRF6.
IRF6 Is Important for PKC-regulated Keratinocyte Differentia-
tion—To establish whether IRF6mediates PKC-regulated kera-
tinocyte differentiation, we first investigated the ability of PMA
to induce IRF6 nuclear translocation. The staining of OKF6
cells with anti-IRF6 antibodies revealed that IRF6 was present
in both the cytoplasmandnucleus of a substantial proportion of
cells, whereas, in other cells, it localized exclusively to the cyto-
plasm (Fig. 3A). PMA did not appear to cause an overall
increase in IRF6 nuclear localization (Fig. 3,A andB). However,
a significant increase in IRF6 nuclear translocation was
observed when the cells were pretreated with the nuclear
export inhibitor leptomycin B (LMB) (Fig. 3, A and B). There-
fore, PKC activation induces the transient nuclear transloca-
tion of IRF6. Gene promoter reporter assays demonstrated that
PKC activation also induces IRF6 activity (Fig. 3C).
We next investigated the importance of IRF6 for PKC-regu-
lated keratinocyte differentiation. As shown in Fig. 4, the IRF6-
FIGURE 1.Activation of IRF6 by RIPK4. A–D, HEK293T cells were transfected
with an IFN (A and B) or ELAM-1 (C and D) gene promoter reporter plasmid
together with expression vectors encoding IRF6 (A and B) and the indicated
Ripk4 proteins (A–D). Gene reporter activity was measured 24 h post-trans-
fection. IRF6 (A andB) andNF-B (C andD) activity are shownas fold increases.
The data are combined from three independent experiments. **, p 0.01. E,
HEK293T cells transiently expressing FLAG-Ripk4 and FLAG-Ripk4 K51R were
lysed 24 h post-transfection. The Ripk4 proteins were immunoprecipitated
from the lysates using anti-FLAG antibodies, and their ability to phosphory-
late GST-IRF6 CTDwasmeasured. The lysates (input) were subjected toWest-
ern blottingwith an anti-FLAG antibody. Data are representative of two inde-
pendent experiments. F, HEK293T cells transiently expressing the indicated
proteinswere lysed 24 h post-transfection. IRF6was immunoprecipitated (IP)
from the lysates using anti-V5 antibodies, followed by Western blotting with
anti-FLAG and anti-V5 antibodies. The asterisk indicates the position of the
anti-V5 antibody heavy chain. The lysates (input) were subjected to Western
blotting with an anti-FLAG antibody. The positions of molecular weight
standards (in kilodaltons) are indicated. The data are representative of three
independent experiments. G, HEK293T cells transiently expressing V5-IRF6
alone or together with either FLAG-Ripk4 or FLAG-Ripk4 K51R were stained
with anti-IRF6 (green) and anti-FLAG (red) antibodies. Scale bars  10 m.
Data are representative of four independent experiments.
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targeting siRNA, which substantially reduced IRF6mRNA (Fig.
4A) and protein levels (data not shown), significantly inhibited
the up-regulation of the keratinocyte differentiation markers
IVL and KRT13 in PMA-treated OKF6 cells (Fig. 4, B and C). It
also reduced the inhibitory effects of PMA on cell proliferation,
asmeasured by cell number (Fig. 4D) and PCNA levels (Fig. 4, E
and F). Likewise, IRF6 knockdown inhibited the up-regulation
of GRHL3 and OVOL1 expression (Fig. 4, G and H), a finding
that is also consistent with these transcriptional regulators of
keratinocyte differentiation being IRF6 target genes (7, 8). The
up-regulation of MAD1 expression was also inhibited by IRF6
knockdown (Fig. 4I). The kinetics of PMA-induced GRHL3,
OVOL1, and MAD1 expression were unaffected (data not
shown). In addition to OKF6 cells (oral keratinocytes), the
PMA-inducible up-regulation of GRHL3, OVOL1, and IVL
expression in epidermal keratinocytes was also IRF6-depen-
dent (Fig. 4, J–L). These data indicate that IRF6 functions in the
PKC pathway to regulate keratinocyte differentiation.
RIPK4 Is Important for the Induction of IRF6-dependent Dif-
ferentiation Genes by PKC—Given the ability of RIPK4 to acti-
vate IRF6 (Fig. 1), we investigated the importance of RIPK4 for
the PMA-inducible expression of the above IRF6-dependent
differentiation genes. RIPK4 knockdown (Fig. 5A) inhibited the
up-regulation of the IRF6 target genes GRHL3 and OVOL1 in
PMA-treated OKF6 cells (Fig. 5, B and C). It also inhibited the
up-regulation of MAD1 expression (Fig. 5D). Consistent with
its importance for keratinocyte differentiation (9, 10), RIPK4
knockdown concomitantly inhibited the up-regulation of IVL
and KRT13 expression in PMA-treated OKF6 cells (Fig. 5, E
and F). PMA-inducibleGRHL3,OVOL1, and IVL expression in
epidermal keratinocytes were likewise inhibited by RIPK4
knockdown (Fig. 5, G–I).
As a complementary approach, the effects of RIPK4 overex-
pressionwere also investigated. The anti-RIPK4 antibody failed
to detect either transfected or endogenous RIPK4. Therefore,
the level of overexpression could not be determined. However,
the ectopic expression of RIPK4 in OKF6 cells (Fig. 5J) signifi-
cantly enhanced the up-regulation ofGRHL3,OVOL1, and IVL
gene expression by PMA (Fig. 5, K–M). GRHL3, OVOL1, and
FIGURE 2. PMA-inducible OKF6 cell differentiation. A–D, OKF6 cells were cultured in the presence of 100 ng/ml PMA or 0.1%DMSO vehicle for up to 48 h. A,
the cells were fixed 48 h post-treatment and stainedwith an anti--tubulin antibody (red), and nuclei were stainedwith DAPI (blue). Scale bars 20m. B, the
viable cell number was enumerated by cell counting. *, p 0.05; **, p 0.01. C and D, cell lysates were subjected to Western blotting with anti-PCNA and
anti-ERK2 (loading control) antibodies (C). The positions of molecular weight standards (in kilodaltons) are indicated. D, PCNA protein levels in DMSO-treated
cells in C were given an arbitrary value of 100%. **, p 0.01. E–I, OKF6 cells were treated with 100 ng/ml PMA or 0.1% DMSO for the indicated times. IVL (E),
KRT13 (F), GRHL3 (G), OVOL1 (H), andMAD1 (I) mRNA levels weremeasured by real-time PCR and are shown as the fold increase relative to DMSO-treated cells.
*, p 0.05; **, p 0.01. All graphical data are combined from three independent experiments.
FIGURE3.PMA-inducible IRF6nuclear translocationandactivation.A and
B, OKF6 cells were pretreatedwith 20 ng/ml leptomycin B (LMB) for 60min or
left untreated. They were then treated with 100 ng/ml PMA or 0.1% DMSO
vehicle for 30 min. A, the cells were stained with an anti-IRF6 antibody (red),
and nuclei were stained with DAPI (blue). Scale bars  10 m. B, quantified
data for IRF6 nuclear translocation in A is presented as the ratio of nuclear to
cytosolic IRF6. *, p  0.05. C, HEK293T cells were transfected with an IFN
genepromoter reporter plasmid togetherwith an IRF6expression vector. The
cells were treated 24 h post-transfectionwith PMAor DMSO for 6 h, and gene
reporter activity was measured. IRF6 activity is shown as a fold increase. **,
p 0.01. The data in B and C are combined from three and four independent
experiments, respectively.
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IVL basal expression were not affected by RIPK4 overexpres-
sion (Fig. 5, K–M). Taken together, this indicates that RIPK4
functions upstream of IRF6 in the PKC pathway to promote
keratinocyte differentiation. However, we cannot exclude the
possibility that RIPK4 may promote keratinocyte differentia-
tion by also activating additional transcriptional regulators (e.g.
NF-B).
A BPS-associated Mutation Inhibits RIPK4-mediated IRF6
Activation—Several mutations in RIPK4 were identified
recently in BPS (19, 20), including a missense mutation
(p.Ile121Asn) in the kinase domain (20). When expressed in
HEK293T cells, a single RIPK4 I121N band was detected by
Western blotting (Fig. 6A). This contrasted with wild-type
RIPK4 but was similar to the kinase-dead RIPK4mutant RIPK4
K51R, therefore suggesting that RIPK4 I121N is catalytically
inactive. This was confirmed by performing in vitro kinase
assays on RIPK4 I121N that had been immunoprecipitated
from transfected cells. RIPK4 I121N could not autophosphory-
late (Fig. 6B) and, hence, could not phosphorylate the GST-
IRF6 CTD fusion protein (Fig. 6C). Gene promoter reporter
assays demonstrated that the RIPK4 I121Nmutant cannot acti-
vate IRF6 (Fig. 6D) or NF-B (data not shown). RIPK4 I121N
was also unable to form a complex with coexpressed IRF6 (Fig.
6E) or induce IRF6 nuclear translocation (Fig. 6F). The
p.Ile121Asn mutation, therefore, prevents the activation of
IRF6 (and NF-B) by RIPK4.
Ser-413 and Ser-424 in IRF6 Are Important for Its RIPK4-
mediated Activation—As mentioned, phosphorylation repre-
sents a critical step in IRF activation. We recently identified
Ser-413 and Ser-424 (Fig. 7A) as regulatory phosphorylation
sites in IRF6 (24). Therefore, the importance of these residues
for the activation of IRF6 by RIPK4was investigated. Themuta-
tion of Ser-413 to alanine (i.e. IRF6 S413A) significantly
reduced the activation of IRF6 by RIPK4 (Fig. 7B). RIPK4-me-
diated IRF6 activationwas severely inhibited by themutation of
Ser-424 to alanine (i.e. IRF6 S424A), whereas the IRF6 S413A/
S424A mutant was inactive in this assay (Fig. 7B). Therefore,
Ser-413 and Ser-424 are both critical for the activation of IRF6
by RIPK4. This conclusion is further supported by the findings
that combined mutation of Ser-413 and Ser-424 to the phos-
phomimetic glutamic acid resulted in the IRF6mutant (i.e. IRF6
S413E/S424E) exhibiting trans-activator activity comparable
with that of wild-type IRF6 following its coexpression with
RIPK4 and that the IRF6 S413E/S424E trans-activator function
was not further potentiated by RIPK4 coexpression (Fig. 7C).
RIPK4 did, however, enhance the activities of the IRF6 S413E
and IRF6 S424E mutants (Fig. 7C).
RIPK4 Is Also Important for PKC-regulated IRF6 Expres-
sion—It has been reported recently that IRF6 can regulate its
own transcription (8). In view of the data above, we investigated
whether RIPK4 can regulate IRF6 expression. Activation of the
PKC pathway by PMA resulted in robust up-regulation of IRF6
expression in OKF6 cells (Fig. 8A) as well as epidermal kerati-
nocytes (Fig. 8B). Notably, RIPK4 knockdown inhibited the up-
regulation of IRF6 expression (Fig. 8, A and B). Conversely,
RIPK4 overexpression potentiated IRF6 expression in PMA-
treated cells (Fig. 8C). IRF6 basal expression was not signifi-
cantly affected by RIPK4 knockdown (Fig. 8, A and B), or by
RIPK4 overexpression (Fig. 8C). Similarly, RIPK4 expression
was also unaffected by IRF6 knockdown (data not shown). Col-
FIGURE 4. Effects of IRF6 knockdown on PMA-inducible keratinocyte dif-
ferentiation. A–L, OKF6 cells (A–I)and (J–L) human epidermal keratinocytes
were transfected with IRF6-targeting (black columns) or control non-target-
ing (white columns) siRNA. A–I, 48 h post-transfection (A), IRF6 mRNA levels
were measured by real-time PCR. IRF6 mRNA levels in cells transfected with
the control non-targeting siRNAweregivenanarbitrary valueof 100%. **,p
0.01. B and C, OKF6 cells were treated with 100 ng/ml PMA or 0.1% DMSO
vehicle for 24 h. IVL (B) and KRT13 (C) mRNA levels were measured by real-
time PCR and are shown as the fold increase relative to DMSO-treated cells. *,
p 0.05.D–F, OKF6 cells were treatedwith 100 ng/ml PMA or 0.1%DMSO for
48 h and (D) viable cell number then enumeratedby cell counting. *, p 0.05.
E, cells were lysed and subjected to Western blotting with anti-PCNA and
anti-ERK2 (loading control) antibodies. F, PCNA protein levels in cells trans-
fected with the control non-targeting siRNA and subsequently treated with
DMSOas in Eweregiven an arbitrary valueof 100%. *,p0.05.G–I, OKF6 cells
were treatedwith 100 ng/ml PMAor 0.1%DMSO for 2 h (OVOL1), 6 h (GRHL3),
and 24 h (MAD1). GRHL3 (G), OVOL1 (H), and MAD1 (I) mRNA levels were
measured by real-time PCR and are shown as the fold increase relative to
DMSO-treated cells. *, p 0.05. J–L, 72 h post-transfection, epidermal kerati-
nocytes were treated with 100 ng/ml PMA or 0.1% DMSO for 6 h (GRHL3 and
OVOL1) and 24 h (IVL). GRHL3 (J), OVOL1 (K), and IVL (L) mRNA levels were
measured by real-time PCR and are shown as the fold increase relative to
DMSO-treated cells. *, p 0.05; **, p 0.01. All graphical data are combined
from at least three independent experiments.
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lectively, these data indicate that RIPK4 also plays a role in the
regulation of IRF6 gene expression by the PKC pathway.
DISCUSSION
RIPK4 and IRF6 are key regulators of keratinocyte differen-
tiation (4–6, 9, 10), and their mutation causes the related con-
genital syndromes BPS and popliteal pterygium syndrome,
respectively (17, 19, 20). These syndromes are characterized by
various epidermal abnormalities, including orofacial clefting,
skinwebbing, syndactyly, and genital deformities. The data pre-
sented here suggest that not only do RIPK4 and IRF6 function
in the same signaling pathway to regulate keratinocyte differ-
entiation, but RIPK4 also directly regulates IRF6. Our findings
may therefore help to explain how mutations in RIPK4 cause
epidermal disorders such as BPS.
Themolecular pathways inwhich RIPK4 and IRF6 operate to
regulate keratinocyte differentiation are not well understood,
althoughprior studies indicate that RIPK4 functions in the PKC
pathway (10–14). PKCactivation promotes keratinocyte differ-
entiation by inducing the expression of various differentiation-
associated genes, including IVL (29–33). We have shown here
that RIPK4 and IRF6 are important for the induction of kerati-
nocyte differentiation by the PKC pathway. Significantly, IRF6
nuclear translocation and trans-activator function were
induced downstream of PKC signaling. Similarly, transfection
studies demonstrated the regulation of IRF6 nuclear transloca-
tion and trans-activator function by RIPK4. Therefore, RIPK4
and IRF6 likely mediate keratinocyte differentiation, at least in
part, by operating as a signaling axis downstream of PKC acti-
vation. RIPK4 has also been shown recently to regulate Wnt
signaling by enhancing the stability of the LEF-1/TCF tran-
scriptional coactivator -catenin (16). Therefore, the RIPK4-
IRF6 axis may also be a feature of other signaling pathways (e.g.
Wnt pathway) that contribute to the regulation of epidermal
development.
The inhibitory effects of RIPK4 and IRF6 knockdown on
keratinocyte differentiation coincided with reduced GRHL3,
OVOL1, andMAD1 expression. GRHL3 regulates keratinocyte
differentiation and epidermal development through its interac-
tion with the transcription factor LMO4 and by recruiting the
Trithorax complex to the promoters of differentiation-associ-
ated genes (e.g. transglutaminase 1) (37–39). OVOL1 promotes
differentiation by repressing c-Myc transcription (40), whereas
MAD1 antagonizes c-Myc transcriptional activity (43). Inter-
estingly, the strength and duration of c-Myc activity appear to
influence the balance between keratinocyte proliferation and
differentiation (44). Given that GRHL3 and OVOL1 are direct
FIGURE 5. Effects of RIPK4 knockdown and overexpression on PMA-in-
ducible keratinocyte differentiation. A–I, OKF6 cells (A–F) and human epi-
dermal keratinocytes (G–I) were transfected with RIPK4-targeting (black col-
umns) or control non-targeting (white columns) siRNA. A–F, 48 h post-
transfection (A) RIPK4 mRNA levels were measured by real-time PCR. RIPK4
mRNA levels in cells transfected with the control non-targeting siRNA were
given an arbitrary value of 100%. **, p  0.01. B–F, OKF6 cells were treated
with 100 ng/ml PMA or 0.1% DMSO vehicle for 2 h (OVOL1), 6 h (GRHL3), and
24 h (MAD1, IVL, and KRT13). GRHL3 (B), OVOL1 (C), MAD1 (D), IVL (E), and
KRT13 (F) mRNA levels weremeasured by real-time PCR and are shown as the
fold increase relative to DMSO-treated cells. *, p 0.05; **, p 0.01. G–I, 72 h
post-transfection, the epidermal keratinocytes were treated with 100 ng/ml
PMA or 0.1% DMSO vehicle for 6 h (GRHL3 and OVOL1) and 24 h (IVL). GRHL3
(G), OVOL1 (H), and IVL (I) mRNA levels were measured by real-time PCR and
are shown as the fold increase relative toDMSO-treated cells. *, p 0.05. J–M,
OKF6 cells were transfectedwith a FLAG-Ripk4 expression plasmid (black col-
umns) or empty plasmid (white columns). 24 h post-transfection (J), Ripk4
mRNA levelsweremeasuredby real-timePCR and are shown relative to those
of HPRT. ND, not detected. Cell lysates were subjected to Western blotting
with anti-FLAG (Ripk4) and anti-HSP90 (loading control) antibodies. K–M, the
cells were treated with 100 ng/ml PMA or 0.1% DMSO for 2 h (OVOL1), 6 h
(GRHL3), and 24 h (IVL). GRHL3 (K), OVOL1 (L), and IVL (M) mRNA levels were
measured by real-time PCR and are shown as the fold increase relative to
DMSO-treated cells. **, p  0.01. The data are combined from three inde-
pendent experiments.
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IRF6 target genes (7, 8), RIPK4 likely promotes keratinocyte
differentiation, at least in part, by inducing their IRF6-mediated
transcription.Whether IRF6 also directly controlsMAD1 tran-
scription is not known. However, its delayed induction in
response to PMA suggests that IRF6 indirectly regulatesMAD1
expression.
PKC, which has been shown previously to form a complex
with RIPK4 (11), is an important regulator of keratinocyte dif-
ferentiation (45–47). For example, PKC promotes IVL gene
expression by up-regulating the expression of the transcription
factor Kruppel-like factor 4 (KLF4) (47). Significantly, KLF4 has
been found recently to be an IRF6 target gene (7, 8). Therefore,
PKC may regulate KLF4 and, hence, IVL transcription via
RIPK4-mediated IRF6 activation. This would position PKC so
that it could also control the expression of other transcriptional
regulators of keratinocyte differentiation, including GRHL3
and OVOL1.
Our findings may also provide a molecular basis for how
mutations in RIPK4 cause BPS (19, 20). As shown here, the
p.Ile121Asn mutation inhibits the kinase activity of RIPK4,
thereby preventing it from phosphorylating and activating
IRF6. BPS is a more severe developmental disorder than those
where IRF6 ismutated (e.g.popliteal pterygium syndrome) (17),
which is consistent with the positioning of RIPK4 upstream of
IRF6. Prior studies have demonstrated an important role for
FIGURE 6. Effects of a BPS-associated mutation on the activation of IRF6
byRIPK4.A–C, HEK293T cells transiently expressing FLAG-Ripk4, FLAG-Ripk4
I121N, or FLAG-Ripk4 K51R were lysed 24 h post-transfection. A, the lysates
were subjected to Western blotting (WB) with an anti-FLAG antibody. The
positions of molecular weight standards (in kilodaltons) are indicated. B and
C, FLAG-Ripk4 and FLAG-Ripk4 I121N were immunoprecipitated from the
lysates using anti-FLAG antibodies and their abilities to autophosphorylate
(B) and phosphorylate GST-IRF6 CTD (C) were measured. The data are repre-
sentative of two independent experiments. D, HEK293T cells were trans-
fected with an IFN gene promoter reporter plasmid together with expres-
sion vectors encoding IRF6 and either Ripk4 or Ripk4 I121N. Gene reporter
activitywasmeasured24hpost-transfection, and IRF6activity is shownas the
fold increase. **, p  0.01. The data are combined from three independent
experiments. E, HEK293T cells transiently expressing the indicated proteins
were lysed 24 hpost-transfection. IRF6was immunoprecipitated (IP) from the
lysates using anti-V5 antibodies, followedbyWesternblottingwith anti-FLAG
and anti-V5 antibodies. The asterisk indicates the position of the anti-V5 anti-
bodyheavy chain. The lysates (input)were subjected toWesternblottingwith
an anti-FLAG antibody. The data are representative of three independent
experiments. F, HEK293T cells transiently coexpressing IRF6 and Ripk4 I121N
were stained with antibodies against IRF6 (green) and anti-FLAG (red) anti-
bodies. Scale bars 10m. The data are representative of four independent
experiments.
FIGURE 7. Identification of RIPK4-dependent regulatory phosphoryla-
tion sites in IRF6. A, schematic of IRF6 in which the positions of Ser-413 and
Ser-424 are indicated. DBD, DNA-binding domain; IAD, IRF association
domain. B andC, HEK293T cellswere transfectedwith an IFNgenepromoter
reporter plasmid together with expression vectors encoding the indicated
proteins. Gene reporter activity was measured 24 h post-transfection, and
IRF6 activity is shownas the fold increase. *,p0.05; **,p0.01. Thedata are
combined from three independent experiments.
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NF-B in the regulation of keratinocyte differentiation (48–
50). In agreement with Kalay et al. (20), we found that the
p.Ile121Asn mutation also abolishes RIPK4-mediated NF-B
activation. Themutation also compromisesWnt signaling (16).
Therefore, the severe manifestation of the p.Ile121Asn muta-
tion is likely to not only be due to impaired signaling by the
RIPK4-IRF6 axis but also to be a consequence of defective sig-
naling by additional developmental pathways, such as the
NF-B and Wnt pathways.
We recently identified Ser-413 and Ser-424 as regulatory
phosphorylation sites in IRF6 (24). Our data here suggest that
RIPK4 likely activates the IRF6 trans-activator function by
phosphorylating both Ser-413 and Ser-424. A sequential, two-
step phosphorylation model has been proposed for IRF activa-
tion (51). In this model, phosphorylation of residues in “site 2”
(e.g. Ser-396 in IRF3) alleviates autoinhibition and facilitates the
phosphorylation of residues in “site 1” (e.g. Ser-386 in IRF3),
which is required for IRF3 activation and dimerization (51).
Ser-413 and Ser-424 correspond, respectively, to Ser-386 and
Ser-396 in IRF3. On the basis of the activation model for IRF3
and ourmutagenesis data for IRF6, Ser-424 likely functions as a
gatekeeper phosphorylation site controlling the subsequent
phosphorylation of Ser-413, which is required for full IRF6 acti-
vation by RIPK4.
Significantly, Ser-424 is mutated in popliteal pterygium syn-
drome (52) as well as squamous cell carcinoma (23). The latter
study also identified several mutations in RIPK4. The
p.Asp205Val mutation, for example, causes replacement of an
invariant aspartic acid residue in the kinase domain of RIPK4
(53), which might be expected to compromise RIPK4 activity,
and hence IRF6 activation. IRF6 expression levels have also
been reported to inversely correlate with tumor invasiveness in
squamous cell carcinoma (8, 54). Therefore, impaired signaling
by the RIPK4-IRF6 axis or loss of IRF6 per semay be important
in squamous cell carcinoma.
RIPK4 is also shown here to be important for the regulation
of IRF6 expression by the PKC pathway. IRF6 gene expression
has been shown previously to be regulated by the binding of the
p63 transcription factor to an enhancer element located 9.7 kb
upstream of the IRF6 transcription start site (55, 56). However,
IRF6-binding sites in the IRF6 gene have been identified, lead-
ing to the suggestion that IRF6 can alsomediate its own expres-
sion (8). Its activation of IRF6 may therefore allow RIPK4 to
further promote keratinocyte differentiation by also up-regu-
lating IRF6 expression.
In conclusion, we have identified and mechanistically
defined a previously unrecognized regulatory relationship
between RIPK4 and IRF6 in the control of keratinocyte differ-
entiation. This could help to explain how mutations in RIPK4
cause BPS. These findings may also be relevant to the develop-
ment of squamous cell carcinoma.
REFERENCES
1. Madison, K. C. (2003) Barrier function of the skin: “la raison d’etre” of the
epidermis. J. Invest. Dermatol. 121, 231–241
2. Blanpain, C., and Fuchs, E. (2009) Epidermal homeostasis: a balancing act
of stem cells in the skin. Nat. Rev. Mol. Cell Biol. 10, 207–217
3. Ratushny, V., Gober,M.D., Hick, R., Ridky, T.W., and Seykora, J. T. (2012)
From keratinocyte to cancer: the pathogenesis andmodeling of cutaneous
squamous cell carcinoma. J. Clin. Invest. 122, 464–472
4. Ingraham, C. R., Kinoshita, A., Kondo, S., Yang, B., Sajan, S., Trout, K. J.,
Malik, M. I., Dunnwald, M., Goudy, S. L., Lovett, M., Murray, J. C., and
Schutte, B. C. (2006) Abnormal skin, limb and craniofacialmorphogenesis
in mice deficient for interferon regulatory factor 6 (Irf6). Nat. Genet. 38,
1335–1340
5. Richardson, R. J., Dixon, J., Malhotra, S., Hardman, M. J., Knowles, L.,
Boot-Handford, R. P., Shore, P., Whitmarsh, A., and Dixon, M. J. (2006)
Irf6 is a key determinant of the keratinocyte proliferation-differentiation
switch. Nat. Genet. 38, 1329–1334
6. Biggs, L. C., Rhea, L., Schutte, B. C., and Dunnwald, M. (2012) Interferon
regulatory factor 6 is necessary, but not sufficient, for keratinocyte differ-
entiation. J. Invest. Dermatol. 132, 50–58
7. de la Garza, G., Schleiffarth, J. R., Dunnwald, M., Mankad, A., Weirather,
J. L., Bonde, G., Butcher, S., Mansour, T. A., Kousa, Y. A., Fukazawa, C. F.,
Houston, D. W., Manak, J. R., Schutte, B. C., Wagner, D. S., and Cornell,
R. A. (2013) Interferon regulatory factor 6 promotes differentiation of the
periderm by activating expression of Grainyhead-like 3. J. Invest. Derma-
tol. 133, 68–77
8. Botti, E., Spallone, G., Moretti, F., Marinari, B., Pinetti, V., Galanti, S., De
FIGURE8.RegulationofPMA-inducible IRF6expressionbyRIPK4.A andB,
OKF6 cells (A) and human epidermal keratinocytes (B) were transfected with
RIPK4-targeting (black columns) or control non-targeting (white columns)
siRNA. 48 (A) or 72 h (B) post-transfection, the cells were treated with 100
ng/ml PMA or 0.1% DMSO vehicle for the indicated times. C, OKF6 cells were
transfected with a FLAG-Ripk4 expression plasmid (black columns) or empty
plasmid (white columns). 24 h post-transfection, the cells were treated with
100 ng/ml PMA or 0.1%DMSO for the indicated times. A–C, IRF6mRNA levels
weremeasuredby real-timePCRandare shownas the fold increase relative to
DMSO-treated cells. *, p  0.05; **, p  0.01. The data are combined from
three independent experiments.
A RIPK4-IRF6 Signaling Axis in Keratinocytes
NOVEMBER 7, 2014•VOLUME 289•NUMBER 45 JOURNAL OF BIOLOGICAL CHEMISTRY 31085









Meo, P. D., De Nicola, F., Ganci, F., Castrignanò, T., Pesole, G., Chimenti,
S., Guerrini, L., Fanciulli, M., Blandino, G., Karin, M., and Costanzo, A.
(2011) Developmental factor IRF6 exhibits tumor suppressor activity in
squamous cell carcinomas.Proc.Natl. Acad. Sci. U.S.A.108, 13710–13715
9. Holland, P., Willis, C., Kanaly, S., Glaccum, M., Warren, A., Charrier, K.,
Murison, J., Derry, J., Virca, G., Bird, T., and Peschon, J. (2002) RIP4 is an
ankyrin repeat-containing kinase essential for keratinocyte differentia-
tion. Curr. Biol. 12, 1424–1428
10. Rountree, R. B., Willis, C. R., Dinh, H., Blumberg, H., Bailey, K., Dean, C.,
Jr., Peschon, J. J., and Holland, P. M. (2010) RIP4 regulates epidermal
differentiation and cutaneous inflammation. J. Invest. Dermatol. 130,
102–112
11. Bahr, C., Rohwer, A., Stempka, L., Rincke, G., Marks, F., and Gschwendt,
M. (2000) DIK, a novel protein kinase that interacts with protein kinase
C. Cloning, characterization, and gene analysis. J. Biol. Chem. 275,
36350–36357
12. Chen, L., Haider, K., Ponda, M., Cariappa, A., Rowitch, D., and Pillai, S.
(2001) Protein kinase C-associated kinase (PKK), a novel membrane-as-
sociated, ankyrin repeat-containing protein kinase. J. Biol. Chem. 276,
21737–21744
13. Muto, A., Ruland, J., McAllister-Lucas, L. M., Lucas, P. C., Yamaoka, S.,
Chen, F. F., Lin, A., Mak, T.W., Núñez, G., and Inohara, N. (2002) Protein
kinase C-associated kinase (PKK) mediates Bcl10-independent NF- B
activation induced by phorbol ester. J. Biol. Chem. 277, 31871–31876
14. Moran, S. T., Haider, K., Ow, Y., Milton, P., Chen, L., and Pillai, S. (2003)
Protein kinase C-associated kinase can activate NFB in both a kinase-de-
pendent and a kinase-independent manner. J. Biol. Chem. 278,
21526–21533
15. Meylan, E., Martinon, F., Thome, M., Gschwendt, M., and Tschopp, J.
(2002) RIP4 (DIK/PKK), a novel member of the RIP kinase family, acti-
vates NF-B and is processed during apoptosis. EMBORep. 3, 1201–1208
16. Huang, X., McGann, J. C., Liu, B. Y., Hannoush, R. N., Lill, J. R., Pham, V.,
Newton, K., Kakunda, M., Liu, J., Yu, C., Hymowitz, S. G., Hongo, J. A.,
Wynshaw-Boris, A., Polakis, P., Harland, R. M., and Dixit, V. M. (2013)
Phosphorylation of Dishevelled by protein kinase RIPK4 regulates Wnt
signaling. Science 339, 1441–1445
17. Kondo, S., Schutte, B. C., Richardson, R. J., Bjork, B. C., Knight, A. S.,
Watanabe, Y., Howard, E., de Lima, R. L., Daack-Hirsch, S., Sander, A.,
McDonald-McGinn, D. M., Zackai, E. H., Lammer, E. J., Aylsworth, A. S.,
Ardinger, H. H., Lidral, A. C., Pober, B. R., Moreno, L., Arcos-Burgos, M.,
Valencia, C., Houdayer, C., Bahuau, M., Moretti-Ferreira, D., Richieri-
Costa, A., Dixon, M. J., and Murray, J. C. (2002) Mutations in IRF6 cause
Van der Woude and popliteal pterygium syndromes. Nat. Genet. 32,
285–289
18. Gorlin, R. J., Sedano, H. O., and Cervenka, J. (1968) Popliteal pterygium
syndrome: a syndrome comprising cleft lip-palate, popliteal and intercru-
ral pterygia, digital and genital anomalies. Pediatrics 41, 503–509
19. Mitchell, K., O’Sullivan, J.,Missero, C., Blair, E., Richardson, R., Anderson,
B., Antonini, D., Murray, J. C., Shanske, A. L., Schutte, B. C., Romano,
R.A., Sinha, S., Bhaskar, S. S., Black,G.C., Dixon, J., andDixon,M. J. (2012)
Exome sequence identifies RIPK4 as the Bartsocas-Papas syndrome locus.
Am. J. Hum. Genet. 90, 69–75
20. Kalay, E., Sezgin, O., Chellappa, V., Mutlu, M., Morsy, H., Kayserili, H.,
Kreiger, E., Cansu, A., Toraman, B., Abdalla, E. M., Aslan, Y., Pillai, S., and
Akarsu, N. A. (2012) Mutations in RIPK4 cause the autosomal-recessive
form of popliteal pterygium syndrome. Am. J. Hum. Genet. 90, 76–85
21. Bartsocas, C. S., and Papas, C. V. (1972) Popliteal pterygium syndrome:
evidence for a severe autosomal recessive form. J. Med. Genet. 9, 222–226
22. Hennekam, R. C., Huber, J., and Variend, D. (1994) Bartsocas-Papas syn-
drome with internal anomalies: evidence for a more generalized epithelial
defect or new syndrome? Am. J. Med. Genet. 53, 102–107
23. Stransky, N., Egloff, A. M., Tward, A. D., Kostic, A. D., Cibulskis, K., Si-
vachenko, A., Kryukov, G. V., Lawrence, M. S., Sougnez, C., McKenna, A.,
Shefler, E., Ramos, A. H., Stojanov, P., Carter, S. L., Voet, D., Cortés, M. L.,
Auclair, D., Berger,M. F., Saksena, G., Guiducci, C., Onofrio, R. C., Parkin,
M., Romkes, M., Weissfeld, J. L., Seethala, R. R., Wang, L., Rangel-Es-
careño, C., Fernandez-Lopez, J. C., Hidalgo-Miranda, A., Melendez-Za-
jgla, J.,Winckler,W., Ardlie, K., Gabriel, S. B., Meyerson,M., Lander, E. S.,
Getz, G., Golub, T. R., Garraway, L. A., and Grandis, J. R. (2011) The
mutational landscape of head and neck squamous cell carcinoma. Science
333, 1157–1160
24. Kwa,M. Q., Nguyen, T., Huynh, J., Ramnath, D., De Nardo, D., Lam, P. Y.,
Reynolds, E. C., Hamilton, J. A., Sweet, M. J., and Scholz, G. M. (2014)
Interferon regulatory factor 6 differentially regulates Toll-like receptor
2-dependent chemokine gene expression in epithelial cells. J. Biol. Chem.
289, 19758–19768
25. Dickson, M. A., Hahn, W. C., Ino, Y., Ronfard, V., Wu, J. Y., Weinberg,
R. A., Louis, D. N., Li, F. P., and Rheinwald, J. G. (2000) Human keratino-
cytes that express hTERT and also bypass a p16(INK4a)-enforced mech-
anism that limits life span become immortal yet retain normal growth and
differentiation characteristics.Mol. Cell Biol. 20, 1436–1447
26. Schindler, U., and Baichwal, V. R. (1994) ThreeNF- B binding sites in the
human E-selectin gene required for maximal tumor necrosis factor -in-
duced expression.Mol. Cell Biol. 14, 5820–5831
27. Pfaffl, M.W. (2001) A newmathematical model for relative quantification
in real-time RT-PCR. Nucleic Acids Res. 29, e45
28. Tamura, T., Yanai, H., Savitsky, D., and Taniguchi, T. (2008) The IRF
family transcription factors in immunity and oncogenesis. Annu. Rev. Im-
munol. 26, 535–584
29. Denning,M. F. (2004) Epidermal keratinocytes: regulation of multiple cell
phenotypes by multiple protein kinase C isoforms. Int. J. Biochem. Cell
Biol. 36, 1141–1146
30. Matsui, M. S., Chew, S. L., and DeLeo, V. A. (1992) Protein kinase C in
normal human epidermal keratinocytes during proliferation and calcium-
induced differentiation. J. Invest. Dermatol. 99, 565–571
31. Długosz, A. A., and Yuspa, S. H. (1994) Protein kinase C regulates kerati-
nocyte transglutaminase (TGK) gene expression in cultured primary
mouse epidermal keratinocytes induced to terminally differentiate by cal-
cium. J. Invest. Dermatol. 102, 409–414
32. Eckert, R. L., Crish, J. F., Efimova, T., Dashti, S. R., Deucher, A., Bone, F.,
Adhikary, G., Huang, G., Gopalakrishnan, R., and Balasubramanian, S.
(2004) Regulation of involucrin gene expression. J. Invest. Dermatol. 123,
13–22
33. Chew, Y. C., Adhikary, G., Wilson, G. M., Reece, E. A., and Eckert, R. L.
(2011) Protein kinase C (PKC)  suppresses keratinocyte proliferation by
increasing p21(Cip1) level by a KLF4 transcription factor-dependent
mechanism. J. Biol. Chem. 286, 28772–28782
34. Watt, F. M. (1989) Terminal differentiation of epidermal keratinocytes.
Curr. Opin. Cell Biol. 1, 1107–1115
35. Watt, F. M. (1983) Involucrin and other markers of keratinocyte terminal
differentiation. J. Invest. Dermatol. 81, 100s-103s
36. Fuchs, E. (1988) Keratins as biochemical markers of epithelial differentia-
tion. Trends Genet. 4, 277–281
37. Ting, S. B., Caddy, J., Hislop, N., Wilanowski, T., Auden, A., Zhao, L. L.,
Ellis, S., Kaur, P., Uchida, Y., Holleran, W. M., Elias, P. M., Cunningham,
J. M., and Jane, S. M. (2005) A homolog of Drosophila grainy head is
essential for epidermal integrity in mice. Science 308, 411–413
38. Yu, Z., Lin, K. K., Bhandari, A., Spencer, J. A., Xu, X.,Wang, N., Lu, Z., Gill,
G.N., Roop,D. R.,Wertz, P., andAndersen, B. (2006) TheGrainyhead-like
epithelial transactivator Get-1/Grhl3 regulates epidermal terminal differ-
entiation and interacts functionally with LMO4. Dev. Biol. 299, 122–136
39. Hopkin, A. S., Gordon, W., Klein, R. H., Espitia, F., Daily, K., Zeller, M.,
Baldi, P., and Andersen, B. (2012) GRHL3/GET1 and trithorax group
members collaborate to activate the epidermal progenitor differentiation
program. PLoS Genet. 8, e1002829
40. Nair, M., Teng, A., Bilanchone, V., Agrawal, A., Li, B., and Dai, X. (2006)
Ovol1 regulates the growth arrest of embryonic epidermal progenitor cells
and represses c-myc transcription. J. Cell Biol. 173, 253–264
41. Teng, A., Nair, M., Wells, J., Segre, J. A., and Dai, X. (2007) Strain-depen-
dent perinatal lethality ofOvol1-deficientmice and identification ofOvol2
as a downstream target of Ovol1 in skin epidermis. Biochim. Biophys. Acta
1772, 89–95
42. Werner, S., Beer, H. D.,Mauch, C., Lüscher, B., andWerner, S. (2001) The
Mad1 transcription factor is a novel target of activin and TGF- action in
keratinocytes: possible role of Mad1 in wound repair and psoriasis.Onco-
gene 20, 7494–7504
A RIPK4-IRF6 Signaling Axis in Keratinocytes
31086 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 289•NUMBER 45•NOVEMBER 7, 2014









43. Lüscher, B. (2012) MAD1 and its life as a MYC antagonist: an update. Eur
J. Cell Biol. 91, 506–514
44. Watt, F. M., Frye, M., and Benitah, S. A. (2008) MYC in mammalian
epidermis: how can an oncogene stimulate differentiation?Nat. Rev. Can-
cer 8, 234–242
45. Deucher, A., Efimova, T., and Eckert, R. L. (2002) Calcium-dependent
involucrin expression is inversely regulated by protein kinase C (PKC)
and PKC. J. Biol. Chem. 277, 17032–17040
46. Adhikary, G., Chew, Y. C., Reece, E. A., and Eckert, R. L. (2010) PKC- and
-, MEKK-1, MEK-6, MEK-3, and p38- are essential mediators of the
response of normal human epidermal keratinocytes to differentiating
agents. J. Invest. Dermatol. 130, 2017–2030
47. Chew, Y. C., Adhikary, G., Xu, W., Wilson, G. M., and Eckert, R. L. (2013)
Protein kinase C  increases Kruppel-like factor 4 protein, which drives
involucrin gene transcription in differentiating keratinocytes. J. Biol.
Chem. 288, 17759–17768
48. Bushdid, P. B., Brantley, D. M., Yull, F. E., Blaeuer, G. L., Hoffman, L. H.,
Niswander, L., andKerr, L.D. (1998) Inhibition ofNF-B activity results in
disruption of the apical ectodermal ridge and aberrant limb morphogen-
esis. Nature 392, 615–618
49. Kanegae, Y., Tavares, A. T., Izpisúa Belmonte, J. C., and Verma, I. M.
(1998) Role of Rel/NF-B transcription factors during the outgrowth of
the vertebrate limb. Nature 392, 611–614
50. Gugasyan, R., Voss, A., Varigos, G., Thomas, T., Grumont, R. J., Kaur, P.,
Grigoriadis, G., and Gerondakis, S. (2004) The transcription factors c-rel
and RelA control epidermal development and homeostasis in embryonic
and adult skin via distinct mechanisms.Mol. Cell Biol. 24, 5733–5745
51. Panne, D., McWhirter, S. M., Maniatis, T., and Harrison, S. C. (2007)
Interferon regulatory factor 3 is regulated by a dual phosphorylation-de-
pendent switch. J. Biol. Chem. 282, 22816–22822
52. Matsuzawa, N., Kondo, S., Shimozato, K., Nagao, T., Nakano, M., Tsuda,
M., Hirano, A., Niikawa, N., and Yoshiura, K. (2010) Twomissense muta-
tions of the IRF6 gene in two Japanese families with popliteal pterygium
syndrome. Am. J. Med. Genet. A 152A, 2262–2267
53. Meylan, E., and Tschopp, J. (2005) The RIP kinases: crucial integrators of
cellular stress. Trends Biochem. Sci. 30, 151–159
54. Restivo, G., Nguyen, B. C., Dziunycz, P., Ristorcelli, E., Ryan, R. J., Özuysal,
Ö. Y., Di Piazza,M., Radtke, F., Dixon,M. J., Hofbauer, G. F., Lefort, K., and
Dotto, G. P. (2011) IRF6 is a mediator of Notch pro-differentiation and
tumour suppressive function in keratinocytes. EMBO J. 30, 4571–4585
55. Thomason, H. A., Zhou, H., Kouwenhoven, E. N., Dotto, G. P., Restivo, G.,
Nguyen, B. C., Little, H., Dixon, M. J., van Bokhoven, H., and Dixon, J.
(2010) Cooperation between the transcription factors p63 and IRF6 is
essential to prevent cleft palate in mice. J. Clin. Invest. 120, 1561–1569
56. Rahimov, F., Marazita, M. L., Visel, A., Cooper, M. E., Hitchler, M. J.,
Rubini,M., Domann, F. E., Govil,M., Christensen, K., Bille, C.,Melbye,M.,
Jugessur, A., Lie, R. T., Wilcox, A. J., Fitzpatrick, D. R., Green, E. D.,
Mossey, P. A., Little, J., Steegers-Theunissen, R. P., Pennacchio, L. A.,
Schutte, B. C., and Murray, J. C. (2008) Disruption of an AP-2 binding
site in an IRF6 enhancer is associated with cleft lip. Nat. Genet. 40,
1341–1347
A RIPK4-IRF6 Signaling Axis in Keratinocytes
NOVEMBER 7, 2014•VOLUME 289•NUMBER 45 JOURNAL OF BIOLOGICAL CHEMISTRY 31087









Reynolds, Matthew J. Sweet, John A. Hamilton and Glen M. Scholz
Mei Qi Kwa, Jennifer Huynh, Jiamin Aw, Lianyi Zhang, Thao Nguyen, Eric C.
Function as a Signaling Axis to Regulate Keratinocyte Differentiation
Receptor-interacting Protein Kinase 4 and Interferon Regulatory Factor 6
doi: 10.1074/jbc.M114.589382 originally published online September 22, 2014
2014, 289:31077-31087.J. Biol. Chem. 
  
 10.1074/jbc.M114.589382Access the most updated version of this article at doi: 
 Alerts: 
  
 When a correction for this article is posted•  
 When this article is cited•  
 to choose from all of JBC's e-mail alertsClick here
  
 http://www.jbc.org/content/289/45/31077.full.html#ref-list-1
This article cites 56 references, 22 of which can be accessed free at
 at UQ Library on September 5, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
